Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(11 sites)

France

Institut de Cancérologie de l'Ouest - Site Angers, Angers

Centre Georges François Leclerc, Dijon

Centre Oscar Lambret, Lille

Institut Paoli Calmettes, Marseille

CHU de Nîmes, Nîmes

Institut Curie - Site Paris, Paris

Centre Eugène Marquis, Rennes

Institut de Cancérologie de l'Ouest - Site Saint Herblain, Saint-Herblain

Centre Paul Strauss, Strasbourg

IUCT-O, Toulouse

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy